bezafibrate
Trade name: Bezalip
Bezafibrate is a fibrate drug used as a lipid-lowering agent to treat hyperlipidaemia. It helps to lower LDL cholesterol and triglyceride in the blood, and increase HDL. — Wikipedia
Clinical trial activity
21 trials · 33 clinical orgs · 0 marketing orgs
Earliest trial started Jun 1, 2006 (NCT00336167)
Timeline
Indications
Approved for
Studied for
- Acute Coronary Syndrome · Phase 4
- Bipolar Disorder · Phase 2
- Carnitine O-Palmitoyltransferase · Phase 3
- Cholangitis · Phase 3
- Cholangitis, Sclerosing · Phase 3
- Cholestasis · Phase 3
- Deficiency Diseases · Phase 2
- Depression · Phase 2
- Diabetes Mellitus, Type 2 · Phase 2
- Dyslipidemias · Phase 2
- Hypercholesterolemia · Phase 4
- Liver Cirrhosis, Biliary · Phase 3
- Mitochondrial Diseases · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Myocardial Infarction · Phase 4
- Self Efficacy · Phase 2/Phase 3
- Ursodeoxycholic Acid · Phase 3
Mechanism of action
Peroxisome proliferator-activated receptor agonist
Bezafibrate is a peroxisome proliferator-activated receptor agonist that acts on all three receptor subtypes (alpha, delta and gamma). Bezafibrate simultaneously targets atherogenic dyslipidemia and insulin resistance without development of overweight; it reduces plasma triglycerides and glucose levels, increases HDL-C and decreases the prevalence of small, dense LDL particles.
Chemistry & pharmacology
SMILES
CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O- Mol. weight
- 361.83 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBezafibrate ↗
- ChEMBLCHEMBL264374 ↗
Also known as
- 2-(p-(2-(p-chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid
- 2-(p-(2-(p-chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid
- befizal
- befizal
- befizal
- benzofibrate
- bezafibrat
- bezafibrat
- bezafibrate
- bezafibrate
- bezafibrate
- bezafibrate
- bezafibrate
- bezafibrate
- bezafibrate
- bezafibrate
- bezafibrate
- bezafibrato
- bezafibrato
- bezafibratum
- bezafibratum
- bezagen xl
- bezalip
- bezalip
- bezalip
- bezalip
- bezalip-mono
- bezatol
- bezatol sr (tn)
- bezatol sr (tn)
- bm 15.075
- bm 15.075
- cedur
- cedur
- difaterol
- fibrazate xl
- liparol xl
- zimbacol xl
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06443606 | Phase 3 | Sep 30, 2024 | Assistance Publique - Hôpitaux de Paris |
| NCT05239468 | Phase 2 | Mar 21, 2022 | Intercept Pharmaceuticals |
| NCT04997811 | Phase 2 | Dec 31, 2021 | Blood Cancer UK, The Dudley Group NHS Foundation Trust, University of Birmingham, University of London, University of Manchester, University of Warwick |
| NCT04751188 | Phase 3 | Oct 2, 2020 | Instituto Mexicano del Seguro Social |
| NCT04309773 | Phase 3 | Mar 31, 2020 | Assistance Publique - Hôpitaux de Paris |
| NCT04594694 | Phase 2 | Oct 2, 2019 | Intercept Pharmaceuticals |
| NCT04561466 | Phase 2/Phase 3 (Phase 3) | Mar 26, 2019 | University of Paris |
| NCT02984982 | Phase 4 | Nov 1, 2016 | Regeneron, Sanofi |
| NCT02937012 | Phase 3 | Oct 1, 2016 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
| NCT02701166 | Phase 3 | Feb 1, 2016 | Erasmus University Rotterdam, Istituto Clinico Humanitas - Rozzano (MI), Italy, Leiden University, Ludwig Maximilians University, Maastricht University, Radboud University, University of Amsterdam, University of Barcelona, University of Groningen, Utrecht University |
| NCT02584504 | Phase 3 | Nov 30, 2015 | Regeneron, Sanofi |
| NCT02481245 | Phase 2 | Sep 1, 2015 | Brain & Behavior Research Foundation, Harvard University |
| NCT02398201 | Phase 2 | Sep 1, 2015 | Newcastle University |
| NCT03649269 | N/A | Jan 1, 2014 | Ciprés Grupo Médico |
| NCT02548832 | Phase 2 | Apr 1, 2013 | University of Guadalajara |
| NCT01654731 | Phase 3 | Oct 1, 2012 | University of Paris |
| NCT02291796 | Phase 4 | Jan 1, 2011 | Instituto Mexicano del Seguro Social |
| NCT01165060 | N/A | Jul 1, 2010 | The Stop ALD Foundation, University of Amsterdam |
| NCT00983788 | Phase 2 | Oct 1, 2009 | University of Copenhagen, University of Paris |
| NCT00506298 | Phase 2 | Jul 1, 2007 | Medicor Research Inc., Zalicus |